Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery

Blood

Volumn 115, Issue 4, 2010, Pages 860-869

  Crooks, Daniel R ^a,b   Ghosh, Manik C ^b   Haller, Ronald G ^c   Tong, Wing Hang ^b   Rouault, Tracey A ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERROCHELATASE; HEME; IRON; IRON REGULATORY PROTEIN 2; IRON SULFUR PROTEIN; MESSENGER RNA; SCAFFOLD PROTEIN; SULFUR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROLEUKEMIA CELL; HEMATOPOIETIC TISSUE; HEME SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEPLETION; IRON TRANSPORT; ISCU MYOPATHY; MOUSE; MUSCLE BIOPSY; MYOBLAST; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; RNA TRANSLATION; SPLEEN; ANIMAL; BIOPSY; BIOSYNTHESIS; CYTOLOGY; ENZYMOLOGY; ERYTHROCYTE; ERYTHROLEUKEMIA; GENE EXPRESSION REGULATION; GENETICS; IRON DEFICIENCY ANEMIA; METABOLISM; MITOCHONDRIAL MYOPATHY; MOUSE MUTANT; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; RNA PROCESSING; SKELETAL MUSCLE; TUMOR CELL LINE;

ANEMIA, IRON-DEFICIENCY; ANIMALS; BIOPSY; CELL LINE, TUMOR; ERYTHROCYTES; FERROCHELATASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME; HUMANS; IRON; IRON REGULATORY PROTEIN 2; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; MICE, MUTANT STRAINS; MITOCHONDRIAL MYOPATHIES; MUSCLE, SKELETAL; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; SULFUR;

EID: 77949328686     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-243105     Document Type: Article

References (49)

1. Kikuchi G, Kumar A, Talmage P, Shemin D. The enzymatic synthesis of delta-aminolevulinic acid. J Biol Chem. 1958;233(5):1214-1219.
2. Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006;1763(7):723-736.
3. Nishida G, Labbe RF. Heme biosynthesis; on the incorporation of iron into protoporphyrin. Biochim Biophys Acta. 1959;31(2):519-524.
4. Cox TC, Bawden MJ, Martin A, May BK. Human erythroid 5-aminolevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. EMBO J. 1991;10(7):1891-1902.
5. Binder R, Horowitz JA, Basilion JP, Koeller DM, Klausner RD, Harford JB. Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′-UTR and does not involve poly(A) tail shortening. EMBO J. 1994;13(8):1969-1980. (Pubitemid 24124530)
6. Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H, Ghosh MC, McConnell JP, Rouault TA. Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood. 2005;106(3):1084-1091. (Pubitemid 41076458)
7. Galy B, Ferring D, Minana B, et al. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood. 2005;106(7):2580-2589. (Pubitemid 41510837)
8. Bloomer J, Bruzzone C, Zhu L, Scarlett Y, Magness S, Brenner D. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. J Clin Invest. 1998;102(1):107-114. (Pubitemid 28323836)
9. Brenner DA, Didier JM, Frasier F, Christensen SR, Evans GA, Dailey HA. A molecular defect in human protoporphyria. Am J Hum Genet. 1992;50(6):1203-1210.
10. Bonkowsky HL, Bloomer JR, Ebert PS, Mahoney MJ. Heme synthetase deficiency in human protoporphyria: demonstration of the defect in liver and cultured skin fibroblasts. J Clin Invest. 1975;56(5):1139-1148.
11. Gouya L, Puy H, Lamoril J, et al. Inheritance in erythropoietic protoporphyria: a common wildtype ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood. 1999;93(6):2105-2110. (Pubitemid 29128515)
12. Wu CK, Dailey HA, Rose JP, Burden A, Sellers VM, Wang BC. The 2.0 A structure of human ferrochelatase, the terminal enzyme of heme biosynthesis. Nat Struct Biol. 2001;8(2):156-160. (Pubitemid 32116069)
13. Dailey HA, Finnegan MG, Johnson MK. Human ferrochelatase is an iron-sulfur protein. Biochemistry. 1994;33(2):403-407.
14. Medlock AE, Dailey HA. Examination of the activity of carboxyl-terminal chimeric constructs of human and yeast ferrochelatases. Biochemistry. 2000;39(25):7461-7467.
15. Sellers VM, Wang KF, Johnson MK, Dailey HA. Evidence that the fourth ligand to the [2Fe-2S] cluster in animal ferrochelatase is a cysteine: characterization of the enzyme from Drosophila melanogaster. J Biol Chem. 1998;273(35):22311-22316.
16. Crouse BR, Sellers VM, Finnegan MG, Dailey HA, Johnson MK. Site-directed mutagenesis and spectroscopic characterization of human ferrochelatase: identification of residues coordinating the [2Fe-2S] cluster. Biochemistry. 1996;35(50):16222-16229.
17. Schneider-Yin X, Gouya L, Dorsey M, Rufenacht U, Deybach JC, Ferreira GC. Mutations in the iron-sulfur cluster ligands of the human ferrochelatase lead to erythropoietic protoporphyria. Blood. 2000;96(4):1545-1549. (Pubitemid 30658489)
18. Dailey HA, Dailey TA, Wu CK, et al. Ferrochelatase at the millennium: structures, mechanisms and [2Fe-2S] clusters. Cell Mol Life Sci. 2000;57(13):1909-1926.
19. Kim YM, Bergonia HA, Muller C, Pitt BR, Watkins WD, Lancaster JR Jr. Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J Biol Chem. 1995;270(11):5710-5713.
20. Sellers VM, Johnson MK, Dailey HA. Function of the [2FE-2S] cluster in mammalian ferrochelatase: a possible role as a nitric oxide sensor. Biochemistry. 1996;35(8):2699-2704.
21. Furukawa T, Kohno H, Tokunaga R, Taketani S. Nitric oxide-mediated inactivation of mammalian ferrochelatase in vivo and in vitro: possible involvement of the iron-sulphur cluster of the enzyme. Biochem J. 1995;310(2):533-538.
22. Taketani S, Adachi Y, Nakahashi Y. Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur J Biochem. 2000;267(15):4685- 4692. (Pubitemid 30619458)
23. Mochel F, Knight MA, Tong WH, et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet. 2008;82(3):652-660.
24. Olsson A, Lind L, Thornell LE, Holmberg M. Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect. Hum Mol Genet. 2008;17(11):1666-1672.
25. Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109(2):280-287. (Pubitemid 30350706)
26. Shepherd M, Dailey TA, Dailey HA. A new class of [2Fe-2S]-cluster- containing protoporphyrin (IX) ferrochelatases. Biochem J. 2006;397(1):47-52. (Pubitemid 44032835)
27. Jones MS, Jones OT. The structural organization of haem synthesis in rat liver mitochondria. Biochem J. 1969;113(3):507-514.
28. Li FM, Lim CK, Peters TJ. An HPLC assay for rat liver ferrochelatase activity. Biomed Chromatogr. 1987;2(4):164-168.
29. Falk JE. Porphyrins and Metalloporphyrins: Their General, Physical and Coordination Chemistry, and Laboratory Methods. Amsterdam, The Netherlands: Elsevier; 1964.
30. Crooks DR, Ghosh MC, Braun-Sommargren M, Rouault TA, Smith DR. Manganese targets m-aconitase and activates iron regulatory protein 2 in AF5 GABAergic cells. J Neurosci Res. 2007;85(8):1797-1809. (Pubitemid 46849627)
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
32. Tong WH, Rouault TA. Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis. Cell Metab. 2006;3(3):199-210.
33. Bonifacino JS, Dell'Angelica EC, Springer TA. Immunoprecipitation. Curr Protoc Protein Sci. 2001;Chapter 9:Unit 98.
34. Shoubridge EA, Johns T, Boulet L. Use of myoblast cultures to study mitochondrial myopathies. Methods Enzymol. 1996;264:465-475. (Pubitemid 26089331)
35. Anguita E, Hughes J, Heyworth C, Blobel GA, Wood WG, Higgs DR. Globin gene activation during haemopoiesis is driven by protein complexes nucleated by GATA-1 and GATA-2. EMBO J. 2004;23(14):2841-2852. (Pubitemid 39013556)
36. Chan RY, Schulman HM, Ponka P. Expression of ferrochelatase mRNA in erythroid and nonerythroid cells. Biochem J. 1993;292(2):343-349. (Pubitemid 23181943)
37. Lake-Bullock H, Dailey HA. Biphasic ordered induction of heme synthesis in differentiating murine erythroleukemia cells: role of erythroid 5-aminolevulinate synthase. Mol Cell Biol. 1993;13(11):7122-7132.
38. Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther. 1987;35(1):57-162.
39. Nilsson R, Schultz IJ, Pierce EL, et al. Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis. Cell Metab. 2009;10(2):119-130.
40. Gelling C, Dawes IW, Richhardt N, Lill R, Muhlenhoff U. Mitochondrial Iba57p is required for Fe/S cluster formation on aconitase and activation of radical SAM enzymes. Mol Cell Biol. 2008;28(5):1851-1861.
41. Wingert RA, Galloway JL, Barut B, et al. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature. 2005;436(7053):1035-1039.
42. Jensen LT, Culotta VC. Role of Saccharomyces cerevisiae ISA1 and ISA2 in iron homeostasis. Mol Cell Biol. 2000;20(11):3918-3927.
43. Magness ST, Tugores A, Brenner DA. Analysis of ferrochelatase expression during hematopoietic development of embryonic stem cells. Blood. 2000;95(11):3568-3577. (Pubitemid 30428493)
44. Hall RE, Henriksson KG, Lewis SF, Haller RG, Kennaway NG. Mitochondrial myopathy with succinate dehydrogenase and aconitase deficiency: abnormalities of several iron-sulfur proteins. J Clin Invest. 1993;92(6):2660-2666.
45. Larsson LE, Linderholm H, Mueller R, Ringqvist T, Soernaes R. Hereditary metabolic myopathy with paroxysmal myoglobinuria due to abnormal glycolysis. J Neurol Neurosurg Psychiatry. 1964;27:361-380.
46. Guillon B, Bulteau AL, Wattenhofer-Donze M, et al. Frataxin deficiency causes upregulation of mitochondrial Lon and ClpP proteases and severe loss of mitochondrial Fe-S proteins. FEBS J. 2009;276(4):1036-1047.
47. Puccio H, Koenig M. Friedreich ataxia: a paradigm for mitochondrial diseases. Curr Opin Genet Dev. 2002;12(3):272-277. (Pubitemid 34663760)
48. Bayot A, Basse N, Lee I, et al. Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors. Biochimie. 2008;90(2):260-269.
49. Kollberg G, Tulinius M, Melberg A, et al. Clinical manifestation and a new ISCU mutation in iron-sulphur cluster deficiency myopathy. Brain. 2009;132(8):2170-2179.